Trial Profile
A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacytidine on ER and PR Expression in Triple Negative Invasive Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Mar 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 Sep 2012 Planned End Date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 10 Mar 2012 Planned End Date changed from 1 Jul 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.